Neuroendocrine colon cancer is a rare and aggressive form of cancer that starts in the cells of the colon with both nerve and ...

This research article is published in the Case Reports in Clinical Radiology, published by Scientific Scholar.Neuroendocrine tumours (NETs) affecting the extrahepatic bile ducts are ...

A panelist discusses how the CABINET trial was a National Cancer Institute (NCI)–supported study conducted by the Alliance ...

Patients treated for advanced neuroendocrine tumors (NETs) are at risk of disease progression ... There are the somatostatin analogs, which for many patients with grade 1 or grade 2 NETs of the GI ...

regardless of primary tumor site or grade. The multicenter, randomized, double-blind, placebo-controlled study enrolled 298 patients in the US. Participants were randomized 2:1 to receive ...

177Lu-edotreotide shows potential to extend progression-free survival in patients with grade 1 or 2 somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Among patients with ...

Grade 1 or Grade 2 somatostatin receptor-positive neuroendocrine tumors of gastroenteric or pancreatic origin (Ki-67 ≤20%) in Europe, the United States, Australia and South Africa. The study ...

Grade 1 or Grade 2 somatostatin receptor-positive neuroendocrine tumors of gastroenteric or pancreatic origin (Ki-67 ≤20%) in Europe, the United States, Australia and South Africa. The study ...

All neuroendocrine carcinomas (NECs) are grade 3b. The Ki-67 or mitotic index are ways of describing how many cells are dividing. A specialist doctor (pathologist) counts the number of cancer cells ...

progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This follows ITM’s announcement on January 28, 2025, that the trial met its primary endpoint.